Showing posts with label Zambia. Show all posts
Showing posts with label Zambia. Show all posts

Thursday, July 31, 2014

African Medical Education is Being Transformed by US Program

Medical education in sub-Saharan Africa is being revitalized and expanded through a U.S.-funded effort that is dramatically increasing enrollment, broadening curricula, upgrading Internet access and providing cutting-edge skills labs and other technologies.
Dr.  Nelson Sewankamb talking with students at Makerere University.
MEPI Principal Investigator, Dr. Nelson Sewankambo, leads a discussion with a group of medical students at Makerere University. Photo by Richard Lord for Fogarty/NIH.
In the first substantial publication by participants of the $130 million Medical Education Partnership Initiative (MEPI), more than 225 authors detailed progress being made at the African institutions. Their reports are in a supplement being published today by the journal Academic Medicine. Begun in 2010, MEPI is funded by the President’s Emergency Plan for AIDS Relief (PEPFAR) and the National Institutes of Health, and is co-administered by NIH’s Fogarty International Center and the Health Resources and Services Administration.
“MEPI is a major venture in international educational innovation that has generated new thinking, energy and optimism in the field of medical education in Africa,” the program partners write in a foreword article to the supplement.
The 32 articles include case studies of national strategies to increase numbers of doctors and health professionals trained; educational innovations such as e-learning and regional training sites; research capacity development, and partnerships that leverage advances across the MEPI network.
MEPI participants provided details of accomplishments made through the program, including:
  • In Zimbabwe, medical student and postgraduate enrollment have both nearly doubled, from 260 in 2010 to 513 in 2013, and the Ministry of Higher Education has committed additional financial support to sustain the progress.
  • A decentralized training network of 14 regional hospitals has been established in Kenya, and has provided instruction for more than 300 medical, nursing, dental and pharmacy students.
  • Internal medicine (IM) physicians were in short supply in Mozambique, so salary supplements, Internet access, and notebook computers were offered to encourage  recruitment, resulting in an increase in IM residents from 10 before MEPI to 75 in 2012.
  • Fourteen new master’s level programs were begun in Zambia, including physiological sciences, pharmacology, anatomy, pathology, microbiology and nursing.
  • A virtual microscopy system was introduced in Zambia, containing 4,000 electronic images, which increased student access and is more cost-effective than optical microscopy using glass slides.
  • A research administration office was created in Ethiopia to assist faculty in grant writing and management, and 18 faculty members were supported to present their research at international conferences.
The supplement on MEPI progress also includes commentaries from global health experts such as former U.S. Global AIDS Coordinator Dr. Eric Goosby, MEPI Coordinating Center principal investigator Dr. Francis G. Omaswa and Fogarty International Center Director Dr. Roger I. Glass.
The critical shortage of physicians, researchers and health care workers across sub-Saharan Africa spurred MEPI’s creation. While the region suffers 25 percent of the global burden of disease, it has only 3 percent of the world’s health care workers, according to the World Health Organization. The impact of HIV/AIDS created an urgent need to increase capacity, wrote Goosby and his co-author Deborah von Zinkernagel, former PEPFAR deputy. “Although concerns arose that resources were being diverted from “services,” it was evident to PEPFAR leadership that the ongoing and expanding needs of the HIV-infected community could not be successfully sustained without increasing the number of trained health professionals,” they added.
By awarding the grants directly to African institutions, MEPI is cultivating sustainable local leadership, Omaswa maintained. “For Africa to accelerate the speed of the ongoing transformation, it is necessary for Africans to step up and take ownership and responsibility for what happens in their own backyards,” he said.
Research is embedded in curricula developed through MEPI, to expand local capacity that will drive innovation. African scientists have already contributed to many “game-changing” HIV-related advances such as development of rapid diagnostics for detecting and monitoring HIV infections, noted Glass and his Fogarty co-authors. “The research perspective provided to students and faculty, the ability to raise and answer questions and the idea that medical knowledge and practice are continually changing are being supported by MEPI sites and will hopefully endure long after the program ends,” they continued.
Initially conceived as a five-year program, MEPI funders and participants are now developing plans for a second phase of investment in Africa’s medical education.
Fogarty, the international component of the NIH, addresses global health challenges through innovative and collaborative research and training programs and supports and advances the NIH mission through international partnerships. For more information, visit: http://www.fic.nih.gov.

Monday, September 30, 2013

Study Evaluates HIV Prevention by Population-wide Testing and Early Treatment

A study in South Africa and Zambia will assess whether house-to-house voluntary HIV testing and prompt treatment of HIV infection, along with other proven HIV prevention measures, can substantially reduce the number of new HIV infections across communities.
The trial, Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)  is sponsored and co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The PopART study will build on the results of the landmark of another study which found that HIV-infected individuals who start treatment early, when their immune systems are relatively healthy, dramatically reduce the risk of transmitting the virus to their heterosexual partners.
“Through this new study, we aim to learn whether the treatment of HIV-infected individuals as a form of HIV prevention, an approach previously tested in roughly 1,800 heterosexual couples where one partner was infected, will be just as effective when implemented across an entire adult population,” said NIAID Director Anthony S. Fauci, M.D. “The study also will tell us whether this method of delivering population-wide HIV treatment as prevention is feasible and cost-effective.”
The trial is being conducted in South Africa and Zambia because the HIV prevalence in those countries is among the highest in the world. An estimated 12.5 percent of adults in Zambia and 17.3 percent of adults in South Africa are infected.
“Mathematical models indicate that if a high proportion of a population can be tested for HIV, and those found to be infected are offered treatment right away, then the rate of new HIV infections could decrease substantially over time,” said Dr. Hayes. “The PopART study is assessing whether this approach works and whether the benefits outweigh the costs — information that could help guide public health policy.”
The PopART study investigators have designed an HIV prevention package that includes
  • Door-to-door, voluntary HIV testing offered at annual intervals
  • Linkage of those who test positive for the virus to care at local health centers
  • Promotion of voluntary medical circumcision to men who are not HIV-infected
  • Promotion of steps to prevent mother-to-child HIV transmission
  • Referral of individuals with other sexually transmitted infections to treatment
  • Provision of condoms
The PopART trial will involve 21 communities in South Africa and Zambia with a total population of 1.2 million. The study team has randomly assigned each community to one of three groups. One group of communities will receive the HIV prevention package along with the opportunity for HIV-infected individuals to begin treatment as soon as they test positive for the virus. The second group will receive the same HIV prevention package, and infected individuals will be offered treatment at the stage of infection recommended by their country’s HIV treatment guidelines. The third group will serve as a control and will receive existing HIV prevention and testing services along with HIV care and treatment according to current national guidelines for their country.
The study team will measure the impact of the two HIV prevention packages by determining the number of new HIV infections among a representative sample of 52,500 adults drawn from the 21 study communities and followed for three years. The study is expected to end in 2019.